Kestra Medical Technologies Inc (KMTS) shares plummeted 12.47% in after-hours trading following the release of its Q2 FY26 financial results. The company reported a loss of $0.64 per share, missing the analyst consensus estimate of a $0.59 loss.
Despite revenue of $22.565 million (up 53% YoY) beating estimates of $20.7 million and raised FY26 revenue guidance to $91 million, investors focused on the widening net loss of $32.8 million compared to $20.6 million in the prior year period. The EPS miss and increased operating expenses ($43.2 million vs. $25.0 million YoY) drove the negative market reaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments